A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies

BACKGROUND: This phase I study investigated the maximum tolerated dose (MTD), safety, pharmacokinetics and antitumor activity of ganetespib in patients with solid malignancies. METHODS: Patients were enrolled in cohorts of escalating ganetespib doses, given as 1 hour IV infusion, once weekly for 3 w...

Descripción completa

Detalles Bibliográficos
Autores principales: Goldman, Jonathan W, Raju, Robert N, Gordon, Gregory A, El-Hariry, Iman, Teofilivici, Florentina, Vukovic, Vojo M, Bradley, Robert, Karol, Michael D, Chen, Yu, Guo, Wei, Inoue, Takayo, Rosen, Lee S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3626541/
https://www.ncbi.nlm.nih.gov/pubmed/23530663
http://dx.doi.org/10.1186/1471-2407-13-152

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3626541/
https://www.ncbi.nlm.nih.gov/pubmed/23530663
http://dx.doi.org/10.1186/1471-2407-13-152

Ejemplares similares